GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » EV-to-FCF

Satellos Bioscience (TSX:MSCL) EV-to-FCF : -0.44 (As of May. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Satellos Bioscience's Enterprise Value is C$6.36 Mil. Satellos Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was C$-14.50 Mil. Therefore, Satellos Bioscience's EV-to-FCF for today is -0.44.

The historical rank and industry rank for Satellos Bioscience's EV-to-FCF or its related term are showing as below:

TSX:MSCL' s EV-to-FCF Range Over the Past 10 Years
Min: -11.77   Med: 0   Max: 1.49
Current: -0.44

During the past 4 years, the highest EV-to-FCF of Satellos Bioscience was 1.49. The lowest was -11.77. And the median was 0.00.

TSX:MSCL's EV-to-FCF is ranked better than
91.03% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs TSX:MSCL: -0.44

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Satellos Bioscience's stock price is C$0.47. Satellos Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.180. Therefore, Satellos Bioscience's PE Ratio for today is At Loss.


Satellos Bioscience EV-to-FCF Historical Data

The historical data trend for Satellos Bioscience's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience EV-to-FCF Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -5.58 -1.26 -0.61

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.26 -4.68 -0.80 -0.52 -0.61

Competitive Comparison of Satellos Bioscience's EV-to-FCF

For the Biotechnology subindustry, Satellos Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Satellos Bioscience's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satellos Bioscience's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Satellos Bioscience's EV-to-FCF falls into.



Satellos Bioscience EV-to-FCF Calculation

Satellos Bioscience's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6.361/-14.501
=-0.44

Satellos Bioscience's current Enterprise Value is C$6.36 Mil.
Satellos Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-14.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Satellos Bioscience  (TSX:MSCL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Satellos Bioscience's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.47/-0.180
=At Loss

Satellos Bioscience's share price for today is C$0.47.
Satellos Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.180.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Satellos Bioscience EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Satellos Bioscience (TSX:MSCL) Business Description

Traded in Other Exchanges
Address
65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines